Keywords
Arthritis, Rheumatoid ×
Eligibility Determination ×
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

199 Search results.

Eligibility Rheumatoid Arthritis NCT01197534

- 1/22/21 - 1 form, 2 itemgroups, 13 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.; ODM derived from: https://clinicaltrials.gov/show/NCT01197534

Eligibility Rheumatoid Arthritis NCT02507752

- 11/24/20 - 1 form, 2 itemgroups, 9 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Observational Quality of Life Study in Participants With Rheumatoid Arthritis Treated With Rituximab; ODM derived from: https://clinicaltrials.gov/show/NCT02507752

Eligibility Effect Assessment Of Periodontal Prophylaxis On Patients With Anti-CCP Positive Early Rheumatoid Arthritis NCT01706874 - Eligibility Patients With Anti-CCP Positive Early Rheumatoid Arthritis NCT01706874

- 11/18/20 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.; ODM derived from: https://clinicaltrials.gov/show/NCT01706874

Eligibility Rheumatoid Arthritis NCT01969604

- 9/28/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Reduction of Daily Sitting Time in Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01969604

Eligibility Rheumatoid Arthritis NCT02219347

- 4/16/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Biomarkers of Remission in Rheumatoid Arthritis (BioRRA); ODM derived from: https://clinicaltrials.gov/show/NCT02219347

Efficacy of ofatumumab in adult patients with active rheumatoid arthritis with inadequate response to methotrexate NCT00611455 - Screen - Vital Signs; Medical Conditions; Eligibility Question; Neurological Examination; ECG

- 3/17/20 - 1 form, 5 itemgroups, 12 items, 1 language
Itemgroups: Vital Signs, Medical Conditions, Eligibility Question, Neurologic Examination, ECG
Study ID: 110635 Clinical Study ID: 110635 Study Title: A double-blind, randomized, placebo controlled, parallel group, multi-center, phase III trial of ofatumumab investigating clinical efficacy in adult patients with active rheumatoid arthritis who had an inadequate response to methotrexate therapy (FINAL ANALYSIS: follow-up period and cumulative safety data across the whole study) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00611455 Sponsor: GlaxoSmithKline Phase: Phase 3 Study Recruitment Status: Completed Generic Name: ofatumumab, Placebo Study Indication: Arthritis, Rheumatoid

Eligibility Rheumatoid Arthritis NCT01667458

- 2/9/20 - 1 form, 2 itemgroups, 10 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab); ODM derived from: https://clinicaltrials.gov/show/NCT01667458

Eligibility Early Rheumatoid Arthritis NCT01185301

- 12/8/19 - 1 form, 2 itemgroups, 17 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA); ODM derived from: https://clinicaltrials.gov/show/NCT01185301

Eligibility DMARD Resistant Rheumatoid Arthritis NCT01593332

- 11/26/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Low Dose Rituximab as a First Line Biologic Therapy for the Treatment of DMARD Resistant Patients With Rheumatoid Arthritis; ODM derived from: https://clinicaltrials.gov/show/NCT01593332

Eligibility Rheumatoid Arthritis NCT02414984

- 7/11/19 - 1 form, 2 itemgroups, 11 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab; ODM derived from: https://clinicaltrials.gov/show/NCT02414984

Eligibility Rheumatoid Arthritis NCT02335606

- 7/4/19 - 1 form, 3 itemgroups, 12 items, 1 language
Itemgroups: Criteria, Inclusion Criteria, Exclusion Criteria
Real World Effectiveness of Abatacept in Rheumatoid Arthritis Patients: a Prospective, Single-arm, Open-label, Multi-center Observational Study in Taiwan; ODM derived from: https://clinicaltrials.gov/show/NCT02335606

Eligibility Rheumatoid Arthritis NCT02328027

- 7/4/19 - 1 form, 2 itemgroups, 18 items, 1 language
Itemgroups: Inclusion Criteria, Exclusion Criteria
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS); ODM derived from: https://clinicaltrials.gov/show/NCT02328027